News
UK National Health Service begins rollout of Oxford coronavirus vaccine
4 January 2021
At 7.30 am today, dialysis patient Brian Pinker became the very first person to be vaccinated as part of the UK’s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, with patients at the Oxford University NHS Hospitals Trust becoming the first to receive this life-saving vaccine.
University of Oxford welcomes regulatory authorisation of coronavirus vaccine
30 December 2020
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
Oxford vaccine stimulates broad antibody and T cell functions
17 December 2020
Today, researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 is induces broad antibody and T cell functions.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
8 December 2020
Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
Seminars
-
Monday, 22 March 2021, 1pm to 2pm
-
Wednesday, 07 April 2021, 1pm to 2pm
-
Monday, 14 June 2021, 2pm to 3pm
COVID OUTBREAK
During the COVID-19 pandemic, the Jenner Institute is taking measures to prevent the spread of the disease. Departments are instructed by the University’s Registrar to continue to work from home where possible, and manage the return to on site working, based on the University guidelines for risk assessments and work prioritisation. This is to restrict contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions:
- No public access to the University.
- On-site activity permitted where it cannot be undertaken remotely, driven by safety, capacity and other factors such as schools reopening/other changes in government guidelines.
- Teaching and assessment are undertaken remotely where possible and, depending on government guidelines, gatherings of staff and students only permitted where essential for teaching and assessment to take place.
UPDATE ON COVID-19 VACCINE Trial
For all information and enquiries regarding the COVID-19 vaccine trial, please visit: https://covid19vaccinetrial.co.uk/.
Latest publications
-
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
Journal article
Tan TK. et al, (2021), Nature communications, 12
-
Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
Journal article
van Doremalen N. et al, (2021), Nature
COVID-19 Response
- Protect our community
- Protect the vulnerable
- Protect yourself
To find out more about the University's COVID-19 response and measures of protection:
SUPPORT OXFORD’S COVID-19 VACCINE RESEARCH
Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible.
If you are interested in supporting this effort, please make a gift here.